As part of the strategic realignment of its US business, the company has filed for voluntary liquidation under Chapter 7 of ...

Wockhardt will exit its loss-making US generic business to focus on antibiotics and diabetes care. The company filed for ...

Mumbai-based pharma major Wockhardt, which is gearing up to launch its promising antibiotic candidate Zaynich soon, on Friday ...

Central Florida individuals and businesses that have filed for liquidation under Chapter 7 of the U.S. Bankruptcy Code include: ...

The company stated that the decision follows years of losses in the US generics segment, with FY25 alone seeing losses of ...

Wockhardt restructures US business, focusing on innovation and exiting generics, filing for voluntary liquidation for ...

Wockhardt announces its exit from the US generics market, shifting focus to its innovative antibiotic and biologicals ...

By exiting the US generics space, the company aims to redirect capital and executive focus toward two key growth areas: novel ...

Pharma company Wockhardt stated in a regulatory filing that it will exit from the US generic drugs market. The move has come after years of sustained losses in the segment, with the company's generics ...

Mumbai: Wockhardt has announced a significant strategic realignment of its U.S. business, marking an exit from the generic ...

Wockhardt Ltd on July 11 said it has decided to exit US generic pharmaceutical segment to unlock capital for high-impact ...